SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

However the trial didn't demonstrate any extra 'synergistic' benefits in combining the drugs, which other GLP-1 plus SGLT2 inhibitor trials have shown. A trial of AstraZeneca's GLP-1 Bydureon ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Both drug classes improve glycemic control ... matched 1:1 on propensity score with those starting treatment with an SGLT2 inhibitor or a DPP-4 inhibitor. In the cohort matched with SGLT2 users ...